Overview

Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status:
Completed

Trial end date:
2017-08-24

Target enrollment:

Participant gender:

Summary

This was a study to determine whether therapy with pazopanib was effective and safe in women with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose cancer had not progressed on first line chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis
Novartis Pharmaceuticals

Collaborator:

GlaxoSmithKline